Amgen and MediLink to collaborate on SCLC combination therapy
Amgen and MediLink Therapeutics have agreed to a research and supply collaboration to develop a combination therapy for extensive-stage small …
Post
-
-
“Strategic market positioning” needed for Ebglyss to rival Dupixent in atopic dermatitis
Eli Lilly’s Ebglyss (lebrikizumab) will require strategic market positioning to differentiate it against more established atopic dermatitis treatments, though it …
-
Bayer and MOMA Therapeutics partner for oncology programme
Bayer has entered a strategic collaboration with MOMA Therapeutics to advance a small molecule oncology programme, leveraging the latter’s KNOMATIC …
-
MHRA puts technology in the spotlight in 2024/25 business plan
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has unveiled a new business plan to build on the launch …
-
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a …
-
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a …
-
ViiV Healthcare to increase annual supply of long-acting HIV PrEP
ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis (PrEP) to at …
-
Innovent and ASK Pharm to commercialise limertinib for lung cancer
Innovent Biologics and Jiangsu Aosaikang Pharmaceutical (ASK Pharm) have signed a strategic partnership agreement for the commercialisation of limertinib to …
-
Neuvivo makes bid to enter ALS arena with immunotherapy candidate
Neuvivo has submitted a New Drug Application (NDA) for its investigational amyotrophic lateral sclerosis (ALS) immunotherapy to the US Food …
-
EMA starts review into hair loss drugs about potential link to suicidal thoughts
The European Medicines Agency (EMA) has started a review of popular anti-baldness and enlarged prostate medicines finasteride and dutasteride over …
-
Oncolytics targets accelerated approval for oncolytic virus therapy
Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II …
-
Activist investor Starboard forges $1bn stake in Pfizer to swing profits
Activist investor Starboard Value has built a $1bn stake in Pfizer to seek a turnaround in the drugmaker’s tumbling share …
-
ProductLife boosts drug development with IntiQuan acquisition
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG's capabilities in …
-
Health Canada approves Telix’s Illuccix label expansion
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in prostate-specific membrane antigen (PSMA) targeted …
-
OnKure and Reneo Pharmaceuticals complete merger
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to operate under …
